SCHEMBL26529784

SCHEMBL26529784

N#Cc1c(F)cccc1OCc1ccc(-c2nnc(C(F)F)o2)cn1

nearest known ligand 0.50

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
HDAC6 Q9UBN7 19/20 0.50
HDAC1 Q13547 2/20 0.41
HDAC8 Q9BY41 1/20 0.41
HDAC5 Q9UQL6 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26530430 0.92 HDAC6 (0.44) HDAC6HDAC1HDAC8HDAC5
SCHEMBL26529834 0.87 HDAC6 (0.51) HDAC6HDAC1
SCHEMBL26529816 0.84 HDAC6 (0.55) HDAC6HDAC1
SCHEMBL26529845 0.84 HDAC6 (0.46) HDAC6HDAC1
SCHEMBL26529852 0.82 HDAC6 (0.48) HDAC6
SCHEMBL26529829 0.82 HDAC6 (0.48) HDAC6
SCHEMBL26125377 0.82 HDAC6 (0.52) HDAC6
SCHEMBL30574375 0.82 HDAC6 (0.52) HDAC6
SCHEMBL26529841 0.82 HDAC6 (0.46) HDAC6HDAC1
SCHEMBL26529848 0.82 HDAC6 (0.46) HDAC6HDAC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023196601-A1 OXADIAZOLE HDAC6 INHIBITORS AND USES THEREOF EIKONIZO THERAPEUTICS, INC. (US) 2023-10-12 WO disclosed
US-20230322747-A1 OXADIAZOLE HDAC6 INHIBITORS AND USES THEREOF EIKONIZO THERAPEUTICS, INC. (US) 2023-10-12 US disclosed
US-20230322747-A1 OXADIAZOLE HDAC6 INHIBITORS AND USES THEREOF EIKONIZO THERAPEUTICS, INC. (US) 2023-10-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230322747-A1 OXADIAZOLE HDAC6 INHIBITORS AND USES THEREOF HDAC6, HDAC1, HDAC11 HDAC6 1/4885HDAC1 2/4885HDAC8 9/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.